Targets › LILRB4
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.
Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance. Receptor for FN1. (UniProt, Q8NHJ6)
Open in Phaseline: the race on LILRB4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience | 6MW5311 bispecific T cell engager antibody with bivalent binding to LILRB4 on tumor cells and mono | LILRB4, CD3E | Phase 1 | AML | Dec 2029 |
AML (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.